-
The FDA has approved a live, oral, vaccine for the prevention of rotavirus gastroenteritis in infants. An earlier vaccine approved for this indication (RotaShield®) was withdrawn in 1999 due to an increased risk of intussusception. In a large trial, of more than 70,000 children, risk of intussusception was not observed with the new vaccine. The new oral rotavirus vaccine will be marketed by Merck & Co., Inc. as Rota Teq®.
-
Healing of Stage II-IV pressure ulcers is associated with use of moist dressings and adequate nutrition. An additional factor for Stage III and Stage IV ulcers is cleansing with soap and water or saline.
-
Three simultaneously published reports from the Women's Health Initiative demonstrate that a low-fat diet did not reduce the risk of breast cancer, colorectal cancer, or cardiovascular disease over 8 years of follow-up.
-
Use of High-Dose Acyclovir in Pityriasis Rosea; Rimonabant in Overweight or Obese Patients; Watchful Waiting vs Repair of Inguinal Hernia in Minimally Symptomatic Men
-
In 2001-2002, an estimated 89.4 million individuals in the United States were nasally colonized with S. aureus and 2.3 million with MRSA.
-
-
-
-
Treatment of Benign Prostatic Hyperplasia; Treatment of Osteoarthritis of the Knee; Refractory Asthma and TNFConnection?; FDA Actions
-
Shan and colleagues examined outcomes of 18 gastrointestinal surgery patients with invasive candidiasis who were treated preemptively based on clinical criteria from 1999 through 2002, and compared them to outcomes of 18 patients treated only on the basis of positive blood cultures or other unequivocal evidence of deep infection from 1995 through 1998.